EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Paroxysmal nocturnal hemoglobinuria–related thrombosis in the era of novel therapies: a 2043-patient-year analysis

Carmelo Gurnari iD, Hussein Awada, Simona Pagliuca iD, Danai Dima iD, Fauzia Ullah iD, Naomi Kawashima iD, Yasuo Kubota iD, Ceylan Colak iD, Valeria Visconte, Bhumika J Patel, Vikram Dhillon, Naimisha Marneni und 4 weitere

Blood · 11.07.2024 · 144 (2) · 145-155

DOI: 10.1182/blood.2024023988 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Blood, erschienen am 11.07.2024. Verfasst von Carmelo Gurnari und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal, Thrombosis, Anticoagulants. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thrombophilia is one of the principal features of paroxysmal nocturnal hemoglobinuria (PNH) and constitutes the main cause of disease morbidity/mortality. Anticomplement treatment has revolutionized the natural history of PNH, with control of the hemolytic process and abolition of thrombotic events (TEs). However, no guidelines exist for the management of thromboembolic complications in this setting, with type and duration of anticoagulation depending on individual practices. Besides, a scarcity of data is present on the efficacy of direct oral anticoagulants (DOACs). Herein, we accrued a large real-world cohort of patients with PNH from 4 US centers to explore features, predictors of TE, and anticoagulation strategies. Among 267 patients followed up for a total of 2043 patient-years, 56 (21%) developed TEs. These occurred at disease onset in 43% of cases, involving more frequently the venous system, typically as Budd-Chiari syndrome. Rate of TEs was halved in patients receiving complement inhibitors (21 vs 40 TEs per 1000 patient-years in untreated cases, with a 2-year cumulative incidence of thrombosis of 3.9% vs 18.3%, respectively), and varied according to PNH granulocytes and erythrocytes clone size, type, disease activity parameters, as well as number (≥2 mutations, or less) and variant allelic frequency of PIGA mutations. Anticoagulation with warfarin (39%), DOACs (37%), and low-molecular weight heparin (16%) was administered for a median of 29 months (interquartile range [IQR], 9-61.8). No thrombotic recurrence was observed in 19 patients treated with DOACs at a median observation of 17.1 months (IQR, 8.9-45) whereas 14 cases discontinued anticoagulation without TE recurrence at a median time of 51.4 months (IQR, 29.9-86.8).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemoglobinuria, ParoxysmalThrombosisAnticoagulantsHumansMaleFemaleMiddle AgedAdultAgedFollow-Up Studies

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
  • Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
  • Department of Clinical Hematology, Centre Hospitalier Régional Universitaire Nancy and Unité Mixte de Recherche 7635, University of Lorraine, Vandoeuvre-lès-Nancy, France.
  • Imaging Institute, Cleveland Clinic, Cleveland, OH.
  • Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI.
  • Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN.

ORCID-Profile: Carmelo Gurnari, Simona Pagliuca, Danai Dima, Fauzia Ullah, Naomi Kawashima, Yasuo Kubota, Ceylan Colak

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Gurnari, C., Awada, H., Pagliuca, S., Dima, D., Ullah, F., Kawashima, N., Kubota, Y., Colak, C., Visconte, V., Patel, B. J., Dhillon, V., Marneni, N., Balasubramanian, S. K., Kishtagari, A., Bat, T., & Maciejewski, J. P. (2024). Paroxysmal nocturnal hemoglobinuria–related thrombosis in the era of novel therapies: a 2043-patient-year analysis. Blood, 144(2), 145-155. https://doi.org/10.1182/blood.2024023988

Vancouver

Gurnari C, Awada H, Pagliuca S, Dima D, Ullah F, Kawashima N, et al. Paroxysmal nocturnal hemoglobinuria–related thrombosis in the era of novel therapies: a 2043-patient-year analysis. Blood. 2024;144(2):145-155. doi:10.1182/blood.2024023988

BibTeX
@article{Gurnari2024,
  author = {Gurnari, Carmelo and Awada, Hussein and Pagliuca, Simona and Dima, Danai and Ullah, Fauzia and Kawashima, Naomi and Kubota, Yasuo and Colak, Ceylan and Visconte, Valeria and Patel, Bhumika J and Dhillon, Vikram and Marneni, Naimisha and Balasubramanian, Suresh Kumar and Kishtagari, Ashwin and Bat, Taha and Maciejewski, Jaroslaw P},
  title = {Paroxysmal nocturnal hemoglobinuria–related thrombosis in the era of novel therapies: a 2043-patient-year analysis},
  journal = {Blood},
  year = {2024},
  volume = {144},
  number = {2},
  pages = {145--155},
  doi = {10.1182/blood.2024023988}
}
Kostenlos starten →